ENDURANT法国注册研究:腹主动脉瘤腔内修复五年患者结局
ENDURANT法国注册研究自2012年起连续纳入20家法国中心的180例腹主动脉瘤腔内修复患者,评估五年结局。结果显示五年总生存率69.9%±3.5%,动脉瘤相关死亡免除率97.6%±1.2%,二次腔内手术免除率90.4%±2.6%,61.6%(45/73)患者瘤囊缩小,结果与近期EVAR注册研究相当。
要点
- 五年总生存率69.9%±3.5%,动脉瘤相关死亡免除率97.6%±1.2%。
- 五年内任何类型内漏免除率70.1%±3.4%,二次腔内手术免除率90.4%±2.6%。
- 61.6%(45/73)患者五年时瘤囊缩小,97.8%(176/180)患者遵循IFU。
核心结论
- ENDURANT France注册研究五年随访显示,生存率、再干预率和内漏免除率与近期EVAR注册研究相当,瘤囊缩小率高。
- 二次手术和动脉瘤破裂率低于纳入老一代器械的法国ACE随机对照试验。
- 该前瞻性注册研究证明在IFU范围内使用Endurant覆膜支架具有良好的五年结局。
研究设计与样本
- ENDURANT France注册研究为前瞻性注册研究,自2012年起从20家法国中心连续纳入180例患者。
- 研究中心包括公立和私立机构及不同规模中心,以尽可能代表法国真实世界经验。
主要发现
- 五年Kaplan-Meier总生存率为69.9%±3.5%,动脉瘤相关死亡免除率为97.6%±1.2%。
- IA型内漏免除率为94.5%±1.7%,任何类型内漏免除率为70.1%±3.4%,二次腔内手术免除率为90.4%±2.6%。
- 61.6%(45/73)患者在五年时显示瘤囊缩小。
- 97.8%(176/180)患者遵循IFU。
临床怎么用
- 在IFU范围内使用Endurant覆膜支架行EVAR可获得良好的五年生存、内漏免除和再干预结局。
- 五年随访中需关注内漏发生及二次腔内手术风险,并评估瘤囊缩小情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endovascular repair is the preferred method of treatment for infrarenal abdominal aortic aneurysms with numerous publications from multiple geographic regions showing excellent patient outcomes. Since the original ACE (Anevrysme de l'aorte abdominale: Chirurgie versus Endoprothese) randomised control trial, studies of French specific population have also contributed significantly to the body of evidence in support of endovascular abdominal aortic repair. METHODS: In the ENDURANT France registry, 180 patients were consecutively enrolled from 20 French centres starting in 2012. Investigational sites included public and private practice and differing centre volumes to be as representative of real world French experience as possible. The aim of this study was to present the five year outcomes from this registry. RESULTS: Instructions for use (IFU) were respected in 97.8% (176/180) of patients. At five years, the Kaplan-Meier overall survival was 69.9% ± 3.5% and the freedom from aneurysm related death was 97.6% ± 1.2%. The freedom from Type IA endoleaks was 94.5% ± 1.7%, freedom from endoleaks of any type was 70.1 ± 3.4%, and freedom from secondary endovascular procedure 90.4% ± 2.6%. In addition, 61.6% (45/73) of patients exhibited sac shrinkage at five years. CONCLUSION: In this five year report of the Endurant France registry, survival, re-intervention, and freedom from endoleak rates were comparable to recent EVAR registries and there was a high sac shrinkage rate. Secondary procedure and aneurysm rupture were lower than those of ACE, the French RCT which included older generation devices. This prospective registry demonstrates favourable five year outcomes of the Endurant stent graft used within IFU.
引用
- Becquemin JP, Haupert S, Issam F, et al. Five Year Patient Outcomes of Endovascular Abdominal Aortic Aneurysm Repair in the ENDURANT France Registry. Eur J Vasc Endovasc Surg. 2020. PMID: 33004284. doi:10.1016/j.ejvs.2020.08.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。